Gartner’s Hype Cycle Predicts Growing Adoption for AI in Clinical Development
To bring products to market, life sciences companies must address the challenges of clinical development processes, including timelines that span a decade or more, dedicated resources, and investments of $2 billion or more. Furthermore, the people who could have benefitted from the new drug or treatment must wait longer to use it.
Gartner®2022 Hype Cycle™ for Life Science Clinical Development points out that CIOs are increasing investments in clinical development optimization to bring products to market more quickly. One area of interest is AI for clinical development, in which Gartner includes WhizAI as a Sample Vendor.
While clinical development will always require time to ensure safety and efficacy, artificial intelligence (AI) can accelerate processes. For example, AI can replace manual processes used to evaluate patients for trials. AI can quickly search through data to find people who meet criteria for different trial phases. AI can also assist with protocol creation, determining the optimal age range for participants and pre-existing conditions that would exclude them while still enabling a large enough population to participate to produce a meaningful trial.
AI can also help researchers use the petabytes of data that clinical development requires and generates to gain insights quickly into the trial and any adverse effects. With AI, it isn’t necessary to wait for someone to analyze data and create a report. Researchers can identify risks immediately, adapt, and increase overall trial quality.
Additionally, scalable AI platforms can use data from the clinical development process to provide insights to all stakeholders. Instead of waiting 6 months or a year for information, the right AI platform can help decision makers gain the insights they need in a matter of weeks.
AI's time-saving abilities can potentially reduce the clinical development cycle from 15 to 10 years or less and significantly reduce costs.
Where Gartner Places AI in Clinical Development on the Hype Cycle
Gartner considers AI in clinical development a high-benefit technology that’s about 2 to 5 years from mainstream adoption. However, Gartner also points out that market penetration is already at 5% to 20% – relatively high for an emerging technology.
One of the reasons that penetration is high is that AI is also key to other technologies on the Hype Cycle, such as:
- AI-augmented safety vigilance
- Clinical data analytics platforms
- Clinical development hyper-automation
- Clinical trial data transparency
- Augmented analytics
AI in clinical development combines multiple AI disciplines, such as machine learning (ML), deep learning (DL), natural language query (NLQ), and natural language generation (NLG). WhizAI leverages these technologies to provide information to stakeholders throughout the clinical development process quickly and accurately, regardless of their data science expertise. The highly scalable platform works on the back end to identify patterns, spot anomalies, and provide insights. NLQ and NLP allow users to ask questions in natural language and receive clear, contextual responses.
The Future of AI in Clinical Development
Greater access to data is proven to bring products to the life sciences market more quickly. In fact, one of the reasons that COVID-19 treatments came to market so quickly was the access to large global data sets and mandates to share information. AI can provide a way to analyze data in weeks rather than months and make it more accessible in other scenarios. In the Hype Cycle report, Gartner summarizes, “AI has the capacity for driving high performance from automated processes involving large data throughput, aiding insight discovery over large datasets and applying machine intelligence to user interactions.”
Those features of AI in clinical development translate to real-world benefits of decreased time from data acquisition to insight, easy access to insights for all stakeholders, and time savings that bring medications to market faster without compromising safety and efficacy.
To learn more about how early adopters of AI in clinical development are benefitting today, contact WhizAI.
Hype Cycle for Life Science Clinical Development, 2022, Jeff Smith and Rohan Sinha, 26 July 2022.
Disclaimer: Gartner and Hype Cycle are registered trademarks and service marks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Subscribe to our blog
People also viewed
A New Era of Personalization: Applying Generative AI to Dynamic Customer Engagement
Webinar Series: Part 4 - Give Your Life Sciences Analytics the ExplAIn Advantage
Adding Up Data Analytics Total Cost of Ownership (TCO) and How to Lower It
High data analytics expenditures don’t have to be a cost of doing business for life sciences companies. WhizAI lowers the total cost of ownership (TCO) while making data insights more accessible to business users. Traditionally, data analytics TCO has been a significant expense for life sciences organizations.
Transforming Life Sciences Commercial Function with AI and Augmented Analytics
In this whitepaper, sponsored by WhizAl, Everest Group explores the business case and profound impact Al and Augmented Analytics can have on the life sciences commercial function across various use cases in Sales, Marketing, and Market Access. They examine what top pharma enterprises are looking for in an augmented analytics tool, a roadmap for how to get started, and a blueprint for adoption.
Augmented Analytics is “On the Rise” on Gartner’s 2022 Hype Cycle for Life Science Commercial Operations
The Gartner® 2022 Hype Cycle™ for Life Science Commercial Operations introduces a new category, Augmented Analytics, this year. WhizAI is listed as a sample vendor in the Augmented Analytics category in this Hype Cycle. This summary report covers the following highlights.
Why Domain Expertise Is Essential for Life Science Analytics
Domain expertise matters. Consider this: Enterprises choose transportation and logistics companies that have created the specific types of services they need. Businesses seek professional services with experience in their industries and look for consultants with good track records in their markets. However, remember that domain expertise benefits extend to analytics platforms, particularly those deployed for life sciences.